我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
11
1 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
1
9.1%
已完成
6
54.5%
招募中
2
18.2%
终止
暂无批准数据
- CardioFocus has commenced a clinical trial (VISION AF) evaluating the OptiShot Pulsed Field Ablation (PFA) System for paroxysmal atrial fibrillation treatment. - The OptiShot system features an ultra-compliant balloon for precise pulsed energy delivery and tissue contact during pulmonary vein isolation. - The first-in-human trial aims to enroll up to 50 patients, with a 12-month follow-up to assess the technology's efficacy through remapping procedures. - Early user feedback highlights confidence in the system's design for improved long-term outcomes in atrial fibrillation ablation.
